Drug to treat canine lymphoma gets FDA approval

Tanovea-CA1, from veterinary cancer therapeutics company VetDC, is expected available to veterinarians in spring 2017

VetDC, Inc., a veterinary cancer therapeutics company, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has granted a conditional approval of Tanovea™-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs.

“This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” stated Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”

Tanovea-CA1 is expected to be available to veterinarians in the spring of 2017, Roy added.

“The conditional approval of Tanovea-CA1 represents a first on multiple levels for veterinary oncology, and we eagerly anticipate adding this very active and promising new drug to our lymphoma fighting arsenal,” noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at VCA-Katonah Bedford Veterinary Center in Bedford Hills, N.Y.

For more information about Tanovea-CA1 and VetDC, visit the Tanovea website or VetDC website.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.